阿司匹林使用与子宫内膜癌风险及生存
本文综述阿司匹林与子宫内膜癌风险及生存关系的证据,涉及肥胖关联、普通剂量与低剂量阿司匹林的药理学差异及潜在抗肿瘤机制。既往研究结果不一致,暴露测量在剂量、时长和频率上不统一,现有证据对子宫内膜癌结局的潜在影响结论矛盾,提示需进一步研究。
要点
- 既往研究对阿司匹林降低子宫内膜癌风险的结论不一致。
- 研究间在记录剂量、时长和频率方面不一致,难以比较。
- 现有证据对子宫内膜癌结局的潜在影响结论矛盾,需进一步研究。
核心结论
- 当前综述的证据对阿司匹林在子宫内膜癌结局方面的潜在影响结论矛盾,提示未来需开展研究以明确阿司匹林对子宫内膜癌生存的影响,尤其需识别可能从阿司匹林使用中获益的特定人群。
研究设计与样本
- 本文为综述,回顾子宫内膜癌与肥胖关联、普通剂量与低剂量阿司匹林的药理学差异及阿司匹林潜在抗肿瘤机制的证据。
主要发现
- 既往研究关于阿司匹林降低子宫内膜癌风险的结论不一致:部分证据提示对肥胖女性有保护作用,其他研究显示这些药物对子宫内膜癌结局可能有不良影响。
- 研究间暴露测量在记录剂量、时长和频率方面不一致,使比较困难。
- 子宫内膜癌癌症死亡率降低的推测机制可能是阿司匹林通过抑制血小板灭活及可能的 prostaglandin E2 抑制来抑制转移。
- 阿司匹林使用可能对子宫内膜癌女性的肥胖相关合并症包括心血管疾病有次要获益。
- 尽管需考虑阿司匹林相关出血作为可能的不良反应,阿司匹林治疗的获益可能超过子宫内膜癌女性的潜在风险。
临床怎么用
- 原文未据此给出推荐。
局限性
- 既往研究关于阿司匹林对子宫内膜癌风险降低的结论不一致。
- 研究间暴露测量在记录剂量、时长和频率方面不一致,使比较困难。
- 当前综述的证据对子宫内膜癌结局的潜在影响结论矛盾,提示未来需开展研究以明确阿司匹林对子宫内膜癌生存的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The role of acetylsalicylic acid (aspirin) as a chemo-preventive and adjuvant therapeutic agent for cancers is generating attention. Mounting evidence indicates that aspirin reduces the incidence and mortality of certain obesity-related cancers, particularly colorectal cancer. In endometrial cancer, previous studies examining the effect of aspirin remain inconsistent as to the reduction in the risk of endometrial cancer. While some evidence indicates protective effects in obese women, other studies have showed a potential deleterious effect of these medications on endometrial cancer outcomes. However, exposure measurement across studies has been inconsistent in recording dose, duration, and frequency of use; thus making comparisons difficult. In this article, we review the evidence for the association between endometrial cancer and obesity, the pharmacological differences between regular- and low-dose aspirin, as well as the potential anti-tumor mechanism of aspirin, supporting a possible therapeutic effect on endometrial cancer. A proposed mechanism behind decreased cancer mortality in endometrial cancer may be a result of inhibition of metastasis via platelet inactivation and possible prostaglandin E2 suppression by aspirin. Additionally, aspirin use in particular may have a secondary benefit for obesity-related comorbidities including cardiovascular disease in women with endometrial cancer. Although aspirin-related bleeding needs to be considered as a possible adverse effect, the benefits of aspirin therapy may exceed the potential risk in women with endometrial cancer. The current evidence reviewed herein has resulted in conflicting findings regarding the potential effect on endometrial cancer outcomes, thus indicating that future studies in this area are needed to resolve the effects of aspirin on endometrial cancer survival, particularly to identify specific populations that might benefit from aspirin use.
引用
- Takiuchi T, Blake EA, Matsuo K, et al. Aspirin use and endometrial cancer risk and survival. Gynecol Oncol. 2017. PMID: 29132875. doi:10.1016/j.ygyno.2017.10.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。